Role of Histone Deacetylase 6 and Histone Deacetylase 6 Inhibition in Colorectal Cancer
Pharmaceutics · 29.12.2023 · 16 (1) · 54
DOI: 10.3390/pharmaceutics16010054 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 29.12.2023. Verfasst von Ana Vuletić und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Oncology, Institute of Oncology and Radiology of Serbia, Pasterova 14, 11000 Belgrade, Serbia. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 254 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Education and Science of the Republic of Serbia, European Commission, Horizon Europe STEPUPIORS Project.
Abstract (Originalsprache)
Histone deacetylase 6 (HDAC6), by deacetylation of multiple substrates and association with interacting proteins, regulates many physiological processes that are involved in cancer development and invasiveness such as cell proliferation, apoptosis, motility, epithelial to mesenchymal transition, and angiogenesis. Due to its ability to remove misfolded proteins, induce autophagy, and regulate unfolded protein response, HDAC6 plays a protective role in responses to stress and enables tumor cell survival. The scope of this review is to discuss the roles of HDCA6 and its implications for the therapy of colorectal cancer (CRC). As HDAC6 is overexpressed in CRC, correlates with poor disease prognosis, and is not essential for normal mammalian development, it represents a good therapeutic target. Selective inhibition of HDAC6 impairs growth and progression without inducing major adverse events in experimental animals. In CRC, HDAC6 inhibitors have shown the potential to reduce tumor progression and enhance the therapeutic effect of other drugs. As HDAC6 is involved in the regulation of immune responses, HDAC6 inhibitors have shown the potential to improve antitumor immunity by increasing the immunogenicity of tumor cells, augmenting immune cell activity, and alleviating immunosuppression in the tumor microenvironment. Therefore, HDAC6 inhibitors may represent promising candidates to improve the effect of and overcome resistance to immunotherapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Experimental Oncology, Institute of Oncology and Radiology of Serbia, Pasterova 14, 11000 Belgrade, Serbia.
- Clinic for Medical Oncology, Institute of Oncology and Radiology of Serbia, Pasterova 14, 11000 Belgrade, Serbia.
ORCID-Profile: Jelena Spasić
Förderung
- Ministry of Education and Science of the Republic of Serbia
- European Commission
- Horizon Europe STEPUPIORS Project
Zitieren
APA
Vuletić, A., Mirjačić Martinović, K., & Spasić, J. (2023). Role of Histone Deacetylase 6 and Histone Deacetylase 6 Inhibition in Colorectal Cancer. Pharmaceutics, 16(1), 54. https://doi.org/10.3390/pharmaceutics16010054
Vancouver
Vuletić A, Mirjačić Martinović K, Spasić J. Role of Histone Deacetylase 6 and Histone Deacetylase 6 Inhibition in Colorectal Cancer. Pharmaceutics. 2023;16(1):54. doi:10.3390/pharmaceutics16010054
BibTeX
@article{Vuleti2023,
author = {Vuletić, Ana and Mirjačić Martinović, Katarina and Spasić, Jelena},
title = {Role of Histone Deacetylase 6 and Histone Deacetylase 6 Inhibition in Colorectal Cancer},
journal = {Pharmaceutics},
year = {2023},
volume = {16},
number = {1},
pages = {54},
doi = {10.3390/pharmaceutics16010054}
}
EUVIMED